These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

331 related articles for article (PubMed ID: 33281098)

  • 21. Targeting pyruvate dehydrogenase kinase signaling in the development of effective cancer therapy.
    Anwar S; Shamsi A; Mohammad T; Islam A; Hassan MI
    Biochim Biophys Acta Rev Cancer; 2021 Aug; 1876(1):188568. PubMed ID: 34023419
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Inhibiting the inhibitors: Targeting anti-apoptotic proteins in cancer and therapy resistance.
    Shahar N; Larisch S
    Drug Resist Updat; 2020 Sep; 52():100712. PubMed ID: 32599435
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Modulation of Mitochondrial Metabolic Reprogramming and Oxidative Stress to Overcome Chemoresistance in Cancer.
    Avolio R; Matassa DS; Criscuolo D; Landriscina M; Esposito F
    Biomolecules; 2020 Jan; 10(1):. PubMed ID: 31947673
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Inside the biochemical pathways of thymidylate synthase perturbed by anticancer drugs: Novel strategies to overcome cancer chemoresistance.
    Taddia L; D'Arca D; Ferrari S; Marraccini C; Severi L; Ponterini G; Assaraf YG; Marverti G; Costi MP
    Drug Resist Updat; 2015 Nov; 23():20-54. PubMed ID: 26690339
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Recent advancements in therapeutic targeting of the Warburg effect in refractory ovarian cancer: A promise towards disease remission.
    Tyagi K; Mandal S; Roy A
    Biochim Biophys Acta Rev Cancer; 2021 Aug; 1876(1):188563. PubMed ID: 33971276
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Glycogen metabolism has a key role in the cancer microenvironment and provides new targets for cancer therapy.
    Zois CE; Harris AL
    J Mol Med (Berl); 2016 Feb; 94(2):137-54. PubMed ID: 26882899
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Long non‑coding RNAs: Key regulators involved in metabolic reprogramming in cancer (Review).
    Liu C; Li H; Chu F; Zhou X; Xie R; Wei Q; Yang S; Li T; Liang S; Lü M
    Oncol Rep; 2021 May; 45(5):. PubMed ID: 33760177
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Emerging targets in lipid metabolism for cancer therapy.
    Terry AR; Hay N
    Trends Pharmacol Sci; 2024 Jun; 45(6):537-551. PubMed ID: 38762377
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Advances in HER2-Targeted Therapy: Novel Agents and Opportunities Beyond Breast and Gastric Cancer.
    Meric-Bernstam F; Johnson AM; Dumbrava EEI; Raghav K; Balaji K; Bhatt M; Murthy RK; Rodon J; Piha-Paul SA
    Clin Cancer Res; 2019 Apr; 25(7):2033-2041. PubMed ID: 30442682
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Histone methyltransferase and drug resistance in cancers.
    Yang C; Zhang J; Ma Y; Wu C; Cui W; Wang L
    J Exp Clin Cancer Res; 2020 Aug; 39(1):173. PubMed ID: 32859239
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Lipid metabolism alteration contributes to and maintains the properties of cancer stem cells.
    Li H; Feng Z; He ML
    Theranostics; 2020; 10(16):7053-7069. PubMed ID: 32641978
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Targeting lipid mediators in cancer biology.
    Sulciner ML; Gartung A; Gilligan MM; Serhan CN; Panigrahy D
    Cancer Metastasis Rev; 2018 Sep; 37(2-3):557-572. PubMed ID: 30136088
    [TBL] [Abstract][Full Text] [Related]  

  • 33. New insights into the mechanisms of multidrug resistance in cancers.
    Montazami N; Aghapour M; Farajnia S; Baradaran B
    Cell Mol Biol (Noisy-le-grand); 2015 Nov; 61(7):70-80. PubMed ID: 26612736
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Therapy Resistance in Cancers: Phenotypic, Metabolic, Epigenetic and Tumour Microenvironmental Perspectives.
    Zahan T; Das PK; Akter SF; Habib R; Rahman MH; Karim MR; Islam F
    Anticancer Agents Med Chem; 2020; 20(18):2190-2206. PubMed ID: 32748758
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Using Epigenetic Therapy to Overcome Chemotherapy Resistance.
    Strauss J; Figg WD
    Anticancer Res; 2016 Jan; 36(1):1-4. PubMed ID: 26722021
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Epigenetic Alterations and Mechanisms That Drive Resistance to Targeted Cancer Therapies.
    Wajapeyee N; Gupta R
    Cancer Res; 2021 Nov; 81(22):5589-5595. PubMed ID: 34531319
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Targeting lipid metabolism for the treatment of anaplastic thyroid carcinoma.
    von Roemeling CA; Copland JA
    Expert Opin Ther Targets; 2016; 20(2):159-66. PubMed ID: 26414044
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Phytochemical Targeting of STAT3 Orchestrated Lipid Metabolism in Therapy-Resistant Cancers.
    Tse C; Warner A; Farook R; Cronin JG
    Biomolecules; 2020 Jul; 10(8):. PubMed ID: 32731620
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Special Issue: New Approaches to Counteract Drug Resistance in Cancer.
    Vasconcelos MH
    Molecules; 2016 Dec; 22(1):. PubMed ID: 28025535
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Overcoming multidrug resistance in cancer: Recent progress in nanotechnology and new horizons.
    Majidinia M; Mirza-Aghazadeh-Attari M; Rahimi M; Mihanfar A; Karimian A; Safa A; Yousefi B
    IUBMB Life; 2020 May; 72(5):855-871. PubMed ID: 31913572
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.